Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Buy
59
MIRM Quote, Financials, Valuation and Earnings
Last price:
$42.25
Seasonality move
:
3.04%
Day range:
$41.22 - $42.47
52-week range:
$23.14 - $48.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.47x
P/B ratio:
8.72x
Volume:
78K
Avg. volume:
445.2K
1-year change:
40.57%
Market cap:
$2B
Revenue:
$186.4M
EPS (TTM):
-$2.07
Analysts' Opinion
-
Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Mirum Pharmaceuticals has an estimated upside of 49.4% from its current price of $42.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $42.17.
Fair Value
-
According to the consensus of 7 analysts, Mirum Pharmaceuticals has 49.4% upside to fair value with a price target of -- per share.
MIRM vs. S&P 500
-
Over the past 5 trading days, Mirum Pharmaceuticals has underperformed the S&P 500 by -3.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mirum Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mirum Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mirum Pharmaceuticals reported revenues of $90.4M.
Earnings Growth
-
Mirum Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mirum Pharmaceuticals reported earnings per share of -$0.30.
Enterprise value:
2B
EV / Invested capital:
3.79x
Price / LTM sales:
6.47x
EV / EBIT:
--
EV / Revenue:
6.67x
PEG ratio (5yr expected):
-2.03x
EV / Free cash flow:
-75.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$223.1M
Return On Assets:
-15.23%
Net Income Margin (TTM):
-32.51%
Return On Equity:
-41.13%
Return On Invested Capital:
-18.16%
Operating Margin:
-14.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $52.3M | $144.7M | $307M | $47.7M | $90.4M | |
| Gross Profit | $42.5M | $118.2M | $223.1M | $37.5M | $69.6M | |
| Operating Income | -$142.6M | -$110.7M | -$96M | -$25.1M | -$12.7M | |
| EBITDA | -$30.7M | -$140.8M | -$60.6M | -$17.1M | -$4.2M | |
| Diluted EPS | -$1.15 | -$4.30 | -$2.07 | -$0.57 | -$0.30 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $138.2M | $196.8M | $215.6M | $388.6M | $386.6M | |
| Total Assets | $141.9M | $235.2M | $364.3M | $650.6M | $667.9M | |
| Current Liabilities | $18.8M | $50.4M | $51.4M | $74.7M | $115.8M | |
| Total Liabilities | $21.6M | $178.8M | $195.1M | $381.6M | $435.9M | |
| Total Equity | $120.3M | $56.4M | $169.3M | $269.1M | $232M | |
| Total Debt | -- | -- | -- | $306M | $307.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$119M | -$88.6M | -$1.2M | -$18.2M | $4M | |
| Cash From Investing | $89M | -$78.4M | -$92.8M | -$182.8M | -$18M | |
| Cash From Financing | $110M | $334.5M | $14.1M | $207.1M | $3.9M | |
| Free Cash Flow | -$138.1M | -$103.9M | -$27.2M | -$18.2M | -$6.2M | |
MIRM
Sector
Market Cap
$2B
$46.1M
Price % of 52-Week High
86.26%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-0.01%
-0.6%
1-Year Price Total Return
40.57%
-30.52%
Beta (5-Year)
1.200
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$41.83
200-day SMA
Buy
Level
$35.18
Bollinger Bands (100)
Buy
Level
39.16 - 43.48
Chaikin Money Flow
Buy
Level
9.9M
20-day SMA
Sell
Level
$43.61
Relative Strength Index (RSI14)
Sell
Level
46.94
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-63.8312
50-day SMA
Buy
Level
$42.14
MACD (12, 26)
Sell
Level
-0.36
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
37.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9693)
Sell
CA Score
(Annual)
Level (-2.149)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.2827)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Stock Forecast FAQ
In the current month, MIRM has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MIRM average analyst price target in the past 3 months is --.
-
Where Will Mirum Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mirum Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Mirum Pharmaceuticals?
Analysts are divided on their view about Mirum Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mirum Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Mirum Pharmaceuticals's Price Target?
The price target for Mirum Pharmaceuticals over the next 1-year time period is forecast to be -- according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MIRM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mirum Pharmaceuticals is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MIRM?
You can purchase shares of Mirum Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mirum Pharmaceuticals shares.
-
What Is The Mirum Pharmaceuticals Share Price Today?
Mirum Pharmaceuticals was last trading at $42.25 per share. This represents the most recent stock quote for Mirum Pharmaceuticals. Yesterday, Mirum Pharmaceuticals closed at $42.17 per share.
-
How To Buy Mirum Pharmaceuticals Stock Online?
In order to purchase Mirum Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
